Tango Therapeutics Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +3.07%.
Did TNGX Beat Earnings? Q2 2025 Results
Tango Therapeutics delivered a disappointing second quarter, missing on both the top and bottom lines as the absence of licensing revenue left a conspicuous gap in its financials. Revenue collapsed 84.0% year-over-year to $3.18 million, falling well short of the $6.70 million consensus estimate, a 52.55% miss driven primarily by the lack of any license revenue in the period, compared to the $12.10 million Tango recorded in Q2 2024 when it licensed a drug discovery program to Gilead. The net loss widened to $38.85 million, or $0.35 per share, missing the $0.34 consensus estimate by 1.92%. However, a significant one-time tailwind looms: Tango and Gilead mutually agreed to shorten their collaboration's research term, meaning the remaining $53.80 million in deferred revenue will be recognized in Q3 2025. Looking further ahead, a clinical data update for lead asset TNG462 is expected in the second half of 2025, with a registrational trial in pancreatic cancer targeted for 2026, as the company's $180.80 million cash runway extends into Q1 2027.
- Decreased collaboration revenue due to lower research costs incurred under the Gilead collaboration
- Absence of license revenue compared to $12.1 million in Q2 2024 from licensing a drug discovery program to Gilead
- Lower R&D expenses from discontinued programs TNG908 and TNG348, partially offset by increased spend on TNG462, TNG456, and TNG961
“TNG462 has the potential to be a best-in-class PRMT5 inhibitor for the treatment of MTAP-del pancreatic and lung cancers, and we look forward to sharing data that support our conviction later this year.”
Tango Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
The remaining $53.8 million in unrecognized deferred revenue from the Gilead collaboration will be recognized as revenue in Q3 2025 following the truncation of the research term. A clinical data update on TNG462 monotherapy is expected in 2H 2025, which is anticipated to inform the initiation of a registrational trial in pancreatic cancer in 2026 and the development strategy for lung cancer. TNG260 clinical data is also expected in 2H 2025. The company expects its $180.8 million in cash, cash equivalents, and marketable securities to fund operations into Q1 2027.
TNGX YoY Financials
TNGX Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.